sintecal 2 mg tabletta
menarini international operations luxembourg sa - a glimepirid -
sintecal 3 mg tabletta
menarini international operations luxembourg sa - a glimepirid -
loperamid-merck 2 mg kapszula
merck kgaa - loperamid-hidroklorid -
enterobene filmtabletta
ratiopharm hungária kft. - loperamid-hidroklorid -
rivastigmine synthon 2 mg/ml belsőleges oldat
synthon bv - rivasztigmin -
sintecal 4 mg tabletta
menarini international operations luxembourg sa - a glimepirid -
sintecal 6 mg tabletta
menarini international operations luxembourg sa - a glimepirid -
cortiment 9 mg retard tabletta
ferring magyarország kft. - budezonid -
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - gyógyszerek obstruktív légúti betegségek, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
duoresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - gyógyszerek obstruktív légúti betegségek, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).